Wakamoto Pharmaceutical Co (TSE:4512) Total Long-Term Assets: 円6,828 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4512 Wakamoto Pharmaceutical Co Ltd TSE:4512
63 GF Score
Price 円269.00
GF Value 円319.94
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Wakamoto Pharmaceutical Co Total Long-Term Assets?

Wakamoto Pharmaceutical Co TSE:4512 -1.10% 63 Total Long-Term Assets is 円6,828 Mil as of Mar. 2026. GuruFocus rates TSE:4512 with a GF Score™ of 63/100 and a GF Value™ of 円319.94 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Wakamoto Pharmaceutical Co's Total Long-Term Assets for the quarter that ended in Mar. 2026 was 円6,828 Mil.

Wakamoto Pharmaceutical Co Total Long-Term Assets Related Terms

Wakamoto Pharmaceutical Co Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Wakamoto Pharmaceutical Co's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wakamoto Pharmaceutical Co Total Long-Term Assets Chart

Wakamoto Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,345.31 6,358.17 6,451.23 6,094.45 6,827.79

Wakamoto Pharmaceutical Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,451.23 6,859.57 6,094.45 6,486.35 6,827.79
TSE:4512
63GF Score
Wakamoto Pharmaceutical Co Ltd TSE:4512
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wakamoto Pharmaceutical Co Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of 円6,828 Mil mean?
Wakamoto Pharmaceutical Co (TSE:4512) has a Total Long-Term Assets of 円6,828 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Wakamoto Pharmaceutical Co and its competitors.
Is Wakamoto Pharmaceutical Co's Total Long-Term Assets too high?
Wakamoto Pharmaceutical Co's current Total Long-Term Assets is 円6,828 Mil. Overall, Wakamoto Pharmaceutical Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Wakamoto Pharmaceutical Co's Total Long-Term Assets compare to ZTS?
Wakamoto Pharmaceutical Co's Total Long-Term Assets of 円6,828 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Drug Manufacturers company?
A good Total Long-Term Assets depends on the Drug Manufacturers industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Wakamoto Pharmaceutical Co and its competitors. Wakamoto Pharmaceutical Co's current Total Long-Term Assets is 円6,828 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wakamoto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co (TSE:4512) is currently considered Modestly Undervalued. The stock's GF Value™ is 円319.94, compared to a current price of 円269.00 — trading 15.9% below its estimated fair value. The current Total Long-Term Assets is 円6,828 Mil. Wakamoto Pharmaceutical Co's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Wakamoto Pharmaceutical Co (TSE:4512), the current Total Long-Term Assets is 円6,828 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Wakamoto Pharmaceutical Co (TSE:4512) Overvalued in 2026?

Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co stock appears to be undervalued. The current stock price of 円269.00 is trading 15.9% below its estimated GF Value™ of 円319.94. GuruFocus considers Wakamoto Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4512:

  • Total Long-Term Assets: 円6,828 Mil
  • GF Value™: 円319.94 vs. price of 円269.00 (15.9% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the TSE:4512 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Wakamoto Pharmaceutical Co Business Description

Address 2-2-2, Nihonbashi Honcho, Chuo-ku, Tokyo, JPN, 103-8330
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.
63GF Score

Get the complete analysis for TSE:4512

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円269.00
Price
円319.94
GF Value